header logo image

Ionis Pharmaceuticals – Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study…

May 1st, 2023 12:11 am

Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks  Marketscreener.com

Read the original here:
Ionis Pharmaceuticals - Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study...

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick